Activity of mammalian secreted phospholipase A2 from inflammatory peritoneal fluid towards PEG-liposomes. Early indications
International Journal of Pharmaceutics , Volume 214 - Issue 1-2 p. 93- 98
Due to an increase in the activity of phospholipase A2 (PLA2) in various inflammatory diseases, this enzyme may play a key role in the degradation of liposomes and the subsequent release of drug when PEG-liposomes passively target inflammatory tissue. The activity of mammalian secreted phospholipase A2 (sPLA2) in casein stimulated peritoneal fluid was tested toward liposomes of different compositions. Early results indicate only a slight degradation of conventional dipalmitoylphosphatidylcholine (DPPC) liposomes as well as DPPC liposomes incorporated with different concentrations of PEG2000. However, the DPPC degradation increased to 7% when inclusion of 30 mol% phosphatidylethanolamine (PE) in the lipid bilayer. The increase in degradation may be due to an improvement of the substrate - as it is well known, that PE is a better substrate for the mammalian sPLA2 than PC. Incorporation of PE into the bilayer may increase the binding properties of the bilayer resulting in improved conditions for the enzymatic attack by sPLA2. In addition, inhibitory zones of Staphylococcus aureus in an agar diffusion test showed that PLA2 from Crotalus atrox venom was able to catalyze the release of gentamicin from PEG-liposomes. In conclusion, this study suggest that degradation of the lipid bilayer of PEG-liposomes by PLA2 result in release of incapsulated drug, e.g. gentamicin and inclusion of PE in the liposomal bilayer, may enhance the activity of the mammalian sPLA2 toward liposomes composed of DPPC.
|, , , , ,|
|International Journal of Pharmaceutics|
|Organisation||Department of Medical Microbiology and Infectious Diseases|
Vermehren, C, Jørgensen, K, Schiffelers, R.M, & Frokjaer, S. (2001). Activity of mammalian secreted phospholipase A2 from inflammatory peritoneal fluid towards PEG-liposomes. Early indications. In International Journal of Pharmaceutics (Vol. 214, pp. 93–98). doi:10.1016/S0378-5173(00)00641-4